No Data
H.C. Wainwright Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $70
Here's Why We're Not At All Concerned With Soleno Therapeutics' (NASDAQ:SLNO) Cash Burn Situation
Positive Outlook for Soleno Therapeutics: Buy Rating Based on Anticipated FDA Approval and Strong Cash Position
Stifel Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $74
Soleno Therapeutics (SLNO) Receives a Buy From Stifel Nicolaus
Cantor Fitzgerald Maintains Soleno Therapeutics(SLNO.US) With Buy Rating, Maintains Target Price $67
No Data
No Data